Naysayers poking at GUSTO again

Genentech Inc. stock fell $2.75 to $46.375 last week as debate on the GUSTO trial of Activase tPA was rekindled, including word that a congressional subcommittee has become involved.

Critics of the drug have contended that the trial, which compared accelerated dosing of Activase with streptokinase, wasn't conducted properly and that the 1 percent absolute benefit provided by tPA doesn't justify its $2,200 cost compared to the $200 cost of SK.

A political note was injected into the debate by word that the House subcommittee on oversight and investigations, headed by Michigan Democrat John Dingell, will look at the conduct of the trial and the cost of the drug. Committee staffers declined to discuss the investigation, but said that

Read the full 1188 word article

How to gain access

Continue reading with a
two-week free trial.